113 related articles for article (PubMed ID: 38769820)
1. Comparison of the therapeutic effects of febuxostat combined with a low-purine diet and allopurinol combined with a low-purine diet on the improvement of gout patients.
Chen X; Ye T; Dai Y; Li P; Zhao X; Yu Y; Wang X; Jiao X; Shen N
Int J Rheum Dis; 2024 May; 27(5):e15165. PubMed ID: 38769820
[TBL] [Abstract][Full Text] [Related]
2. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
[TBL] [Abstract][Full Text] [Related]
3. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
[TBL] [Abstract][Full Text] [Related]
4. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
[TBL] [Abstract][Full Text] [Related]
5. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Wang S
Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
[TBL] [Abstract][Full Text] [Related]
7. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
8. Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
Shen M; Zhang J; Qian K; Li C; Xu W; Gu B; Wang X; Ren Q; Yang L; Yuan H; Su D; Chen X
Clin Rheumatol; 2018 Nov; 37(11):3107-3113. PubMed ID: 30196323
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat for treating chronic gout.
Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients.
Ziga-Smajic N; Skrbo S; Muratovic S; Pehlivanovic B; Lagumdzija D; Omerovic N
Med Arch; 2020 Jun; 74(3):172-176. PubMed ID: 32801430
[TBL] [Abstract][Full Text] [Related]
11. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Wu J; Zhang YP; Qu Y; Jie LG; Deng JX; Yu QH
Int J Rheum Dis; 2019 Aug; 22(8):1445-1451. PubMed ID: 31317680
[TBL] [Abstract][Full Text] [Related]
13. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
14. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
15. Allopurinol for chronic gout.
Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
[TBL] [Abstract][Full Text] [Related]
16. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
17. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS; Ford I; Nuki G; Hallas J; Hawkey CJ; Webster J; Ralston SH; Walters M; Robertson M; De Caterina R; Findlay E; Perez-Ruiz F; McMurray JJV; MacDonald TM;
Lancet; 2020 Nov; 396(10264):1745-1757. PubMed ID: 33181081
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
Gandhi PK; Gentry WM; Ma Q; Bottorff MB
J Manag Care Spec Pharm; 2015 Feb; 21(2):165-75. PubMed ID: 25615006
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Tamura K; Kawai Y; Kiguchi T; Okamoto M; Kaneko M; Maemondo M; Gemba K; Fujimaki K; Kirito K; Goto T; Fujisaki T; Takeda K; Nakajima A; Ueda T
Int J Clin Oncol; 2016 Oct; 21(5):996-1003. PubMed ID: 27017611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]